ResearchResearch summary
Jarisch–Herxheimer reaction in spirochetal infections: 2017 review
A narrative review summarizes Jarisch–Herxheimer reactions after antibiotics for syphilis, Lyme disease, leptospirosis, and relapsing fever; it offers no Candida evidence.
In this pathway
- Current topic
- Jarisch–Herxheimer reaction in spirochetal infections: 2017 reviewCurrent

Bottom line
This 2017 narrative review describes the Jarisch–Herxheimer reaction after antibiotics for several spirochetal infections. It provides context for that defined infection-treatment setting; it is not evidence of a Candida-specific reaction.
Why this source matters
The review distinguishes reported reactions after antibiotic treatment of syphilis, early Lyme disease, leptospirosis, and relapsing fever from claims about Candida or antifungal treatment.
Study and population
This was a narrative review, not a newly recruited study. It covered recent human case reports using a PubMed 1990–2015 indexing rule and older pathogenesis papers found through cross-references.
What was examined
The review assembled prior reports on reaction frequency, symptoms, timing, severity, and possible mechanisms after antibiotic treatment of spirochetal infections. It did not test a single treatment or use a shared comparator.
Results
Reported frequencies ranged from 1% to 100% across unlike studies. Examples include 92/976 leptospirosis cases (9%), 50/129 U.S./Canadian tick-borne relapsing-fever cases (39%), and 89/239 versus 96/199 Ethiopian relapsing-fever cases with penicillin and tetracycline (37% versus 48%). These are not pooled comparisons (Table 1, p. 47; text, pp. 47–48).
Typical symptoms began within 24 hours and resolved hours later, but timing differed by infection: syphilis reactions typically began at 4 hours and subsided by 16 hours; relapsing-fever reactions began at 1–2 hours and subsided by 8 hours (abstract, p. 46; discussion, p. 49). In relapsing fever, the author proposes that rapid uptake of antibiotic-altered spirochetes by polymorphonuclear leukocytes is the earliest likely trigger; TNF, IL-6, and IL-8 rose 2–4 hours after treatment and may contribute to intensity rather than initiate the reaction (pp. 48–50).
Applicability
The human reports concern antibiotic-treated syphilis, early Lyme disease, leptospirosis, and relapsing fever. They do not apply to antifungal treatment, supplements, restrictive diets, or a Candida-specific “die-off” claim, and they cannot predict an individual reaction.
Limitations
The narrative review combines different infections, treatments, and study designs without a common reaction definition or pooled rate; the author notes that observers used different criteria. The proposed mechanism is based on spirochetal experimental evidence and relapsing-fever measurements. Severe outcomes in case reports are not comparable risk estimates and may overlap with severe underlying infection.
Contribution to the evidence
Contextual. The review helps define the antibiotic/spirochete boundary and summarizes heterogeneous reported rates; it contributes no Candida-specific or antifungal evidence.
Practical change
No practical change to Candida guidance. Worsening during a Candida-labelled intervention is not made evidence of benefit by this review.
Funding and conflicts
Funding and conflicts were not reported in the full text.
Source
Read the original publication (journal issue published 11 January 2017; online first 24 October 2016). The article is free to read on PMC; this page links to and paraphrases it.
Study type, population, and sample scale
- Study type
- Narrative review of recent human cases and previously published pathogenesis studies
- Population
- Published reports and studies concerning antibiotic-treated syphilis, early Lyme disease, leptospirosis, and relapsing fever; no new participant population was recruited.
- Sample scale
- No new cohort. The review assembled heterogeneous prior case reports, series, prospective studies, randomized trials, surveys, and meta-analyses; no overall pooled sample was reported.
Results
- The review reports that observed Jarisch–Herxheimer reaction frequencies ranged from 1% to 100% across different studies and treatments; the author attributes this spread partly to differing observer criteria. The estimates are not a pooled rate (Table 1, p. 47; discussion, p. 46).
- In early Lyme disease, Table 1 reports study-specific frequencies of 7% to 30%. In leptospirosis, an earlier review found a reaction in 92 of 976 antibiotic-treated cases (9%) and reported one death; Butler does not establish that the death was caused by the reaction. A historical Malaya penicillin series reported 70 of 84 cases (83%) (Table 1, p. 47; text, pp. 47–48).
- For tick-borne relapsing fever in the United States and Canada, 50 of 129 patients with treatment information had a reaction (39%). A six-study Ethiopian meta-analysis reported reactions in 89 of 239 penicillin-treated patients (37%) and 96 of 199 tetracycline-treated patients (48%); eight deaths were reported among 438 patients overall (Table 1, p. 47; text, p. 48).
- In relapsing fever, the author proposes that rapid uptake of antibiotic-altered spirochetes by polymorphonuclear leukocytes is the earliest likely trigger. TNF, IL-6, and IL-8 rose 2–4 hours after treatment; anti-TNF antibodies prevented or attenuated reactions in the cited studies, supporting a role in intensity rather than initiation (pp. 48–50). This proposed mechanism is specific to spirochetal infection.
- The review describes chills, temperature rise, and worsening rash beginning within 24 hours and resolving hours later. Timing varied: syphilis reactions typically started at 4 hours, peaked at 8 hours, and subsided by 16 hours; relapsing-fever reactions typically started at 1–2 hours, peaked at 4 hours, and subsided by 8 hours (abstract, p. 46; discussion, p. 49).
Limitations
- The review summarizes human reaction frequencies across several infections and treatment regimens.
- It is a narrative review, not a systematic review or new cohort; the included case reports, series, trials, surveys, and meta-analyses use heterogeneous populations and observer criteria, with no common case definition or pooled cross-infection estimate.
- Recent case reports were included when indexed in PubMed during 1990–2015 under Jarisch–Herxheimer reaction, Treponema, Leptospira, or Borrelia; pathogenesis literature was collected through citation cross-referencing.
- No broader protocol, formal inclusion/exclusion rules beyond that case-report search boundary, or missing-data handling was reported.
- The review discusses severe organ effects and rare fatalities in case reports and older infection-specific studies.
- These descriptions do not provide a comparable risk estimate or establish that every severe outcome was caused by the reaction rather than the underlying infection.
- The proposed mechanism draws on experimental work and relapsing-fever patient measurements.
- The author considers rapid uptake of antibiotic-altered spirochetes by polymorphonuclear leukocytes the earliest likely trigger; cytokine rises may contribute to intensity but appear too late to initiate the reaction (pp. 48–50). This mechanistic account is spirochete-specific.
Applies to
- Historical human evidence on acute reactions reported after antibiotic treatment of syphilis, early Lyme disease, leptospirosis, and relapsing fever.
- The review’s account of proposed spirochetal lipoprotein, phagocytosis, and cytokine mechanisms.
Does not apply to
- Candida infection, antifungal treatment, supplements, restrictive diets, or a Candida-specific “die-off” diagnosis.
- Individual prediction of whether a reaction will occur, how severe it will be, or what a person should do about treatment.
Contribution to the current conclusion
Contextual
The review provides cross-infection context for the specific Jarisch–Herxheimer reaction described after antibiotic treatment of spirochetal infections. Its heterogeneous data and proposed mechanisms do not establish a Candida-specific reaction or inform antifungal treatment.
Related evidence mapPractical change or no change
No practical change for Candida questions. The review describes reactions after antibiotics for spirochetal infections and does not support interpreting worsening during a Candida-labelled intervention as treatment benefit.
Funding and conflicts
- Funding
- Not reported in the full text.
- Conflicts
- Not reported in the full text.
- Paper date
- 2017-01-11